Intestinal barrier dysfunction and dysbiosis contribute to development of diseases in liver
and other organs. Physical, immunologic, and microbiologic (bacterial, fungal, archaeal …

A fundamental function of the intestinal epithelium is to act as a barrier that limits interactions
between luminal contents such as the intestinal microbiota, the underlying immune system …

The global incidence of numerous immune-mediated, metabolic, neurodegenerative, and
psychiatric diseases is steadily increasing [1–3]. The increased morbidity of human …

There is evidence that nonalcoholic fatty liver disease (NAFLD) is affected by gut microbiota.
Therefore, we investigated its modifications in pediatric NAFLD patients using targeted …

The gastrointestinal tract (GIT) represents the largest interface between the human organism
and the external environment. In the lumen and upper part of the mucus layer, this organ …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Its
worldwide prevalence is rapidly increasing and is currently estimated at 24%. NAFLD is …

The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic
steatosis, commonly associated with obesity, to non-alcoholic steatohepatitis, which can …

Proton pump inhibitors (PPIs) marked a before and after in the management of gastric acid
related disorders since their introduction to the market in 1989. Due to a novel, highly …

Chronic hepatitis B infection is one of the major etiological causes of liver failure, cirrhosis,
and hepatocellular carcinoma (HCC) worldwide. This condition cannot be completely cured …

Proton pump inhibitors (PPIs) have been increasingly used over the last decades and there
are concerns about overuse and the numerous reported side-effects. It is uncertain whether …